Tomahawk, WI 8/06/2013 (Basicsmedia) – There had recently been many approvals of drugs from the Food and Drug Administration of the United States in this year which had moved on the companies in the pharmaceutical sector to gain effectively in their shares. One such pharmaceutical player is Inovio Pharmaceuticals Inc. (NYSEMKT:INO) with primary focus on the development of new generation vaccines for diseases like cancer and related infections. The company had been presenting successful results related to the clinical stage trials of its vaccines in the recent months to put it in a perfect position to take off for another surge in share prices.

Clinical Trials of H7N9 Vaccine

In the month of July 2013, it was reported that the H7N9 DNA vaccine component that is presently in the clinical trials of Inovio had proved successful in assuring 100% protection of the vaccinated animals from the infection. The results of the clinical trials presented that the vaccine developed by Inovio had not only been effective at generating protection in the tested animals based on hemagluttination inhibition, but had also proved successful to produce strong T-cell responses which is essential to ensure that there is no increase in the severity of the infection. The vaccine under clinical trials at the Inovio Pharmaceuticals had thus proved to be effective in limiting down the spread of the infection of H7N9 virus in a pandemic setting.

Phase I study of Pennvax–B HIV Vaccine

The company had further reported that Pennvax –B HIV vaccine used in combination with Cellectra had presented high level of effectiveness in the Phase I study of the vaccine. The trials of this preventive HIV vaccine had been conducted in two phases named as HVTN 070 and HVTN 080, in which the vaccine was delivered in combination with the CELLECTRA electoration delivery device. It was observed that the results produced in the patients tested for the CD4 CD8 T-cell responses were durable and strong and had thereby presented significant improvements in the cellular immunity. It is further worth noting that the CD8 T-cell responses were particularly strong at fighting against chronic infections such as cancer.

Financial status

 All such positive results related to the development stage trials of the pipeline product candidates had resulted in a rally of 115% increase in the share prices for the previous month of trading. However, the financial performance of the pharmaceutical company had not been highly attractive for the past few years as Inovio had reported nothing but losses for the past 30 years of business operations. It had been reported that the company had generated net sales of $3.90 million with losses of $20.30 million for the past 12 months.

As the company is presently generating lower sales and net losses for the consecutive quarter, the shares had been rallying only due to the product developments that had been reported in the recent months. Though such results are quite encouraging it is always essential to keep in mind that even such developments in the pharmaceutical sector could in the end turn out to be disastrous to the investors. As the industry is highly riskier, it is essential that the investors make cautious moves on the stock of Inovio Pharmaceuticals without getting carried away by the recent rally in prices.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.